<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492567</url>
  </required_header>
  <id_info>
    <org_study_id>K171004J</org_study_id>
    <secondary_id>2017-A02965-48</secondary_id>
    <nct_id>NCT03492567</nct_id>
  </id_info>
  <brief_title>Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.</brief_title>
  <acronym>MUCO-OS</acronym>
  <official_title>Study of Circulating Monocytes as Predictive Biomarker of Osteoclastogenesis in Cystic Fibrosis-related Bone Loss. Impact of CFTR Correctors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaincre la Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to look for risk factors of developing osteoporosis in patients with
      cystic fibrosis.

      Blood cells called monocytes will be obtained from a blood sample. These monocytes will make
      possible to form another class of cells called osteoclasts in the laboratory. These latter
      cells are responsible for bone degradation and therefore promote the increase of bone
      fragility. The research will focus on the characterization of these cells to better
      understand their potential (low, medium or high) to increase bone fragility in patients with
      cystic fibrosis.

      Finally the action of CFTR modulators on these bone cells will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to characterize the profile of circulating monocytes as predictive
      biomarker of osteoclastogenesis in CF related bone disease.

      Investigators will evaluate the presence and regulation of CD115 (MCSF receptor) and CD265
      (RANK) membrane receptors of circulating monocytes of cystic fibrosis patients.

      They will also analyze the impact of the F508del CFTR mutation on the differentiation of
      monocytes into osteoclasts. We will 1) Quantify the training and functional activity of
      osteoclasts and, 2) Test in vitro the effects of correctors and potentiators of CFTR on the
      resorption activity of differentiated osteoclasts.

      The study will be explained to patients and they only will have one blood test.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotype of CD14 monocytes/osteoclasts</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vitro test of CFTR modulators</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Blood monocyte precursors/osteoclasts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood draw (max 15 ml)</description>
    <arm_group_label>Blood monocyte precursors/osteoclasts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with cystic fibrosis

          -  attending the Paris Cochin adult CF centre

          -  with at least F508del mutation (homozygote or heterozygote patients)

        Exclusion Criteria:

          -  patients younger than 18

          -  absence of signed consent

          -  patients without a F508del mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique HUBERT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique HUBERT, PhD</last_name>
    <phone>+ 33 1.58.41.23.78</phone>
    <email>dominique.hubert@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline TOURTE</last_name>
    <phone>+33 1 58 41 11 90</phone>
    <email>caroline.tourte@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique HUBERT, PhD</last_name>
      <phone>+ 33 1.58.41.23.78</phone>
      <email>dominique.hubert@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>CFTR</keyword>
  <keyword>CFTR modulators</keyword>
  <keyword>Monocyte</keyword>
  <keyword>Osteoclast</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

